Athersys has filed for bankruptcy and secured a deal to sell off its assets to long-standing partner and regenerative medicine company Healios.
After Athersys made a last-ditch attempt in the fall to salvage the company in the wake of an unsatisfactory trial of an ischemic stroke cell therapy, the biotech has decided to sell all assets to Healios and file for bankruptcy.
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
After tweaking a phase 3 clinical trial for the ischemic stroke cell therapy MultiStem with the blessing of the FDA and moving forward with an enrollment goal of 300 patients, Athersys now reports that the sample size is insufficient to achieve the primary endpoint.
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys Director Jane Wasman Appointed Board Chair
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights